标题:Puerarin increases the chemosensitivity of hepatocellular carcinoma cells
作者:Wu, Zhen; Wu, Jing; Fang, Ping; Kan, Shifeng
作者机构:[Wu, Zhen] Shandong Univ, Hosp 2, Dept Clin Lab, Jinan 250033, Shandong, Peoples R China.; [Wu, Jing] Shandong Univ, Hosp 2, Dept Pharm, Jinan 25003 更多
通讯作者:Kan, SF
通讯作者地址:[Kan, SF]Shandong Univ, Qilu Hosp, Dept Clin Lab, 115 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
来源:ONCOLOGY LETTERS
出版年:2017
卷:14
期:3
页码:3006-3010
DOI:10.3892/ol.2017.6524
关键词:puerarin; cisplatin; human hepatocellular carcinoma cell line HepG2;; chemosensitivity
摘要:The present study investigated the effect of puerarin (Pu) on the sensitivity of HepG2 human hepatocellular carcinoma (HCC) cells to chemotherapeutic drugs to determine the possible mechanism. HepG2 cells were treated with different concentrations of Pu and cisplatin (CDDP), alone or in combination. MTT assay was used to determine the inhibitory effects of the different drugs on HepG2 cells. Cell morphology was observed by inverted microscopy. The expression of B-cell lymphoma 2 (BcI-2) and Bax protein was measured by western blot analysis. Pu and CDDP, alone or in combination, inhibited the proliferation of HepG2 cells. The inhibitory effect of CDDP combined with Pu on HepG2 cells was significantly higher than that of the single drug treatments (p < 0.01). In addition, compared with the single drug groups, cellular morphology was significantly altered and the apoptotic rate of cells and the expression of Bax protein were significantly increased (p < 0.01). However, the expression of Bcl-2 protein was significantly decreased (p < 0.01) in the combined drug group. In conclusion, Pu can increase the sensitivity of HCC to chemotherapeutic drugs, enhance the inhibitory effect of chemotherapeutic drugs on cell proliferation and synergistically induce apoptosis of HepG2 cells. The mechanism is likely related to the upregulation of Bax protein and the downregulation of Bcl-2 protein.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026292405&doi=10.3892%2fol.2017.6524&partnerID=40&md5=a2d604434f159116c2d05a01c78a7280
TOP